Samir R. Patel - 03 Jan 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
03 Jan 2025
Net transactions value
+$125
Form type
4
Filing time
07 Jan 2025, 16:30:03 UTC
Previous filing
30 Dec 2024
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX Ordinary Shares, par value $0.0001 per share Award $125 +208,000 +0% $0.000600 5,249,511,500 03 Jan 2025 PranaBio Investments LLC F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 91,396,000 03 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +152,672,000 $0.000000 152,672,000 03 Jan 2025 Ordinary Shares, par value $0.0001 per share 152,672,000 $0.000600 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 On January 3, 2025, the Reporting Person acquired 208,000 Ordinary Shares at a purchase price of $0.0006 per Ordinary Share.
F3 The stock options have an exercise price of $0.000655 per Ordinary Share.